# A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

> **NCT05692180** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 200 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Benralizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05692180
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-05
- **Primary completion:** 2030-05-05
- **Final completion:** 2032-05-16
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05692180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05692180, "A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05692180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*